Veea (NASDAQ:VEEA – Get Free Report) and Simulations Plus (NASDAQ:SLP – Get Free Report) are both small-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.
Risk and Volatility
Veea has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Simulations Plus has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.
Profitability
This table compares Veea and Simulations Plus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veea | N/A | N/A | -20.86% |
| Simulations Plus | 14.15% | 6.16% | 5.68% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veea | 0 | 0 | 0 | 0 | 0.00 |
| Simulations Plus | 0 | 1 | 5 | 1 | 3.00 |
Simulations Plus has a consensus price target of $51.40, indicating a potential upside of 69.13%. Given Simulations Plus’ stronger consensus rating and higher possible upside, analysts clearly believe Simulations Plus is more favorable than Veea.
Earnings and Valuation
This table compares Veea and Simulations Plus”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veea | N/A | N/A | -$30,000.00 | N/A | N/A |
| Simulations Plus | $70.01 million | 8.72 | $9.95 million | $0.49 | 62.02 |
Simulations Plus has higher revenue and earnings than Veea.
Insider & Institutional Ownership
25.9% of Veea shares are owned by institutional investors. Comparatively, 78.1% of Simulations Plus shares are owned by institutional investors. 71.0% of Veea shares are owned by company insiders. Comparatively, 19.4% of Simulations Plus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Simulations Plus beats Veea on 11 of the 12 factors compared between the two stocks.
About Veea
Veea Inc. provides computing, multiaccess multiprotocol communications, edge storage, and cybersecurity solutions. The company offers multiaccess edge computing (MEC) platform that redefines connectivity and computing at the edge by integrating functions of servers, network attached storage (NAS), routers, firewalls, Wi-Fi Access Points, IoT gateways, and 4G and 5G connections; and Veea Edge Platform enables direct connections from the optical fiber, cellular, and satellite networks. It also provides VeeaHub STAX, an edge computing product integrated with wireless access, including Wi-Fi 6; VeeaHub that offers connectivity options for pro indoor smart edge applications; and VeeaHub Outdoor that integrates with wireless connectivity for smart edge applications in outdoor and industrial environments. The company also offers TROLLEE, a smart shopping cart platform; the VeeaHub toolkit; and Veea AdEdge, an advertising platform. Veea Inc. was founded in 2014 and is headquartered in New York, New York.
About Simulations Plus
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Receive News & Ratings for Veea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veea and related companies with MarketBeat.com's FREE daily email newsletter.
